Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Suspended 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 6Thoracic 2Gynecologic 2Gastrointestinal 2Dermatologic 2Breast 2Plasma cell 1Other hematologic neoplasm 1Lymphoid 1CNS 1

Conditions

Melanoma 105Skin Neoplasms 17Neoplasm Metastasis 15Neoplasms 10Uveal Melanoma 9Carcinoma, Renal Cell 9Carcinoma, Non-Small-Cell Lung 9Kidney Neoplasms 6Colorectal Neoplasms 6Carcinoma, Merkel Cell 5Breast Neoplasms 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Ovarian Neoplasms 4Head and Neck Neoplasms 4Lung Neoplasms 3Carcinoma, Transitional Cell 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Prostatic Neoplasms 2Lymphoma 2Eye Neoplasms 2Carcinoma, Hepatocellular 2Urogenital Neoplasms 1Turcot syndrome 1Sezary Syndrome 1Sarcoma, Synovial 1

Interventions

pembrolizumab 10Nivolumab 5Gemcitabine 4durvalumab 3Specimen Handling 3Sirolimus 3Magnetic Resonance Spectroscopy 3Docetaxel 3Cryosurgery 3Cisplatin 3Blood Specimen Collection 3tremelimumab 2temsirolimus 2pertuzumab 2pegilodecakin 2enzalutamide 2cabozantinib 2alvocidib 2Vorinostat 2Trastuzumab 2Ritonavir 2Radiotherapy 2Radiosurgery 2Psychiatric Rehabilitation 2Paclitaxel 2Oxaliplatin 2Interleukin-2 2Cyclophosphamide 2Carboplatin 2Biopsy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Interleukin-2 × Dermatologic × Clear all
NCT07410494 2026-02-18

SELECT-CAR-NK

Essen Biotech

Phase 1/2 Recruiting
85 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Carcinoma, Hepatocellular, Liver Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute

NCT03970382 2022-08-18

A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors

PACT Pharma, Inc.

Phase 1 Suspended
21 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Melanoma, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡